CN102349881A - 一种左卡尼汀薄膜衣片及其制备方法 - Google Patents
一种左卡尼汀薄膜衣片及其制备方法 Download PDFInfo
- Publication number
- CN102349881A CN102349881A CN2011103283600A CN201110328360A CN102349881A CN 102349881 A CN102349881 A CN 102349881A CN 2011103283600 A CN2011103283600 A CN 2011103283600A CN 201110328360 A CN201110328360 A CN 201110328360A CN 102349881 A CN102349881 A CN 102349881A
- Authority
- CN
- China
- Prior art keywords
- levocarnitine
- coated tablets
- film coated
- coating layer
- lubricant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 title claims abstract description 91
- 229960001518 levocarnitine Drugs 0.000 title claims abstract description 89
- 239000003826 tablet Substances 0.000 title abstract description 14
- 238000002360 preparation method Methods 0.000 title abstract description 13
- 239000010409 thin film Substances 0.000 title abstract 4
- 239000000463 material Substances 0.000 claims abstract description 23
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 14
- 239000000945 filler Substances 0.000 claims abstract description 11
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 10
- 239000000314 lubricant Substances 0.000 claims abstract description 10
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 10
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 10
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 10
- 239000001856 Ethyl cellulose Substances 0.000 claims abstract description 9
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 9
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 8
- 239000008101 lactose Substances 0.000 claims abstract description 8
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 8
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims abstract description 5
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims abstract description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 5
- 229920000881 Modified starch Polymers 0.000 claims abstract description 4
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims abstract description 4
- 235000019700 dicalcium phosphate Nutrition 0.000 claims abstract description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims abstract description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims abstract description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 3
- 238000000576 coating method Methods 0.000 claims description 32
- 239000011248 coating agent Substances 0.000 claims description 24
- 239000007941 film coated tablet Substances 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 15
- 239000007921 spray Substances 0.000 claims description 14
- 238000005507 spraying Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 238000007789 sealing Methods 0.000 claims description 9
- 229920001249 ethyl cellulose Polymers 0.000 claims description 8
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 8
- 230000001476 alcoholic effect Effects 0.000 claims description 7
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 5
- -1 hydroxypropyl Chemical group 0.000 claims description 5
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 229950005770 hyprolose Drugs 0.000 claims description 4
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 3
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 3
- 238000002372 labelling Methods 0.000 claims description 2
- 238000009702 powder compression Methods 0.000 claims description 2
- 239000002994 raw material Substances 0.000 abstract description 10
- 230000008569 process Effects 0.000 abstract description 8
- 238000010298 pulverizing process Methods 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 238000012216 screening Methods 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 239000011247 coating layer Substances 0.000 abstract 6
- 239000010408 film Substances 0.000 abstract 2
- 238000002955 isolation Methods 0.000 abstract 2
- 235000010944 ethyl methyl cellulose Nutrition 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 229920003087 methylethyl cellulose Polymers 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 19
- 238000005516 engineering process Methods 0.000 description 13
- 239000010410 layer Substances 0.000 description 12
- 238000004090 dissolution Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000037149 energy metabolism Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 238000007907 direct compression Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 201000009623 Myopathy Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000003257 anti-anginal effect Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000021472 generally recognized as safe Nutrition 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110328360 CN102349881B (zh) | 2011-10-26 | 2011-10-26 | 一种左卡尼汀薄膜衣片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 201110328360 CN102349881B (zh) | 2011-10-26 | 2011-10-26 | 一种左卡尼汀薄膜衣片及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102349881A true CN102349881A (zh) | 2012-02-15 |
CN102349881B CN102349881B (zh) | 2013-06-26 |
Family
ID=45573600
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 201110328360 Active CN102349881B (zh) | 2011-10-26 | 2011-10-26 | 一种左卡尼汀薄膜衣片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102349881B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102525992A (zh) * | 2012-03-09 | 2012-07-04 | 徐奎 | L-α-甘油磷酸胆碱薄膜衣片及其制备方法 |
CN104224759A (zh) * | 2014-09-28 | 2014-12-24 | 天津市聚星康华医药科技有限公司 | 一种左旋肉碱口腔速溶膜及其制备方法 |
CN104511018A (zh) * | 2013-09-27 | 2015-04-15 | 北京诚济制药有限公司 | 一种改善左卡尼汀片强吸湿性和溶出行为的处方和工艺 |
CN112826803A (zh) * | 2021-02-24 | 2021-05-25 | 东北制药集团沈阳第一制药有限公司 | 一种左卡尼汀片及其制备方法 |
JP7588973B2 (ja) | 2019-06-24 | 2024-11-25 | 大塚製薬株式会社 | レボカルニチン含有錠剤 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1345235A (zh) * | 1999-03-26 | 2002-04-17 | 生物合成股份公司 | 特别适合于直接压片制备片剂的具有高含量l-肉碱或烷酰基l-肉碱的颗粒 |
EP2042164A1 (en) * | 2006-06-23 | 2009-04-01 | Takeda Pharmaceutical Company Limited | Stabilized solid preparation |
-
2011
- 2011-10-26 CN CN 201110328360 patent/CN102349881B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1345235A (zh) * | 1999-03-26 | 2002-04-17 | 生物合成股份公司 | 特别适合于直接压片制备片剂的具有高含量l-肉碱或烷酰基l-肉碱的颗粒 |
EP2042164A1 (en) * | 2006-06-23 | 2009-04-01 | Takeda Pharmaceutical Company Limited | Stabilized solid preparation |
Non-Patent Citations (5)
Title |
---|
康毅: "乳糖的粉体特性及直接压片", 《第二届药用辅料(国际)学术研讨会暨口服固体制剂辅料的研究与应用论文集》 * |
李安荣等: "陈香露白露薄膜衣片的研制", 《中国药房》 * |
李小娜等: "薄膜包衣在中药防潮中的应用", 《中草药》 * |
蒋贤武等: "左卡尼汀片处方及制备工艺研究", 《上海医药》 * |
黄朝霞: "粉末直接压片工艺的进展", 《现代食品与药品杂志》 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102525992A (zh) * | 2012-03-09 | 2012-07-04 | 徐奎 | L-α-甘油磷酸胆碱薄膜衣片及其制备方法 |
CN104511018A (zh) * | 2013-09-27 | 2015-04-15 | 北京诚济制药有限公司 | 一种改善左卡尼汀片强吸湿性和溶出行为的处方和工艺 |
CN104511018B (zh) * | 2013-09-27 | 2017-08-18 | 北京诚济制药股份有限公司 | 一种改善左卡尼汀片强吸湿性和溶出行为的处方和工艺 |
CN104224759A (zh) * | 2014-09-28 | 2014-12-24 | 天津市聚星康华医药科技有限公司 | 一种左旋肉碱口腔速溶膜及其制备方法 |
JP7588973B2 (ja) | 2019-06-24 | 2024-11-25 | 大塚製薬株式会社 | レボカルニチン含有錠剤 |
CN112826803A (zh) * | 2021-02-24 | 2021-05-25 | 东北制药集团沈阳第一制药有限公司 | 一种左卡尼汀片及其制备方法 |
CN112826803B (zh) * | 2021-02-24 | 2024-01-19 | 东北制药集团沈阳第一制药有限公司 | 一种左卡尼汀片及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN102349881B (zh) | 2013-06-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102349881B (zh) | 一种左卡尼汀薄膜衣片及其制备方法 | |
CN103070864B (zh) | 一种瑞格列奈和盐酸二甲双胍药物组合物及其制备方法 | |
CN112494440B (zh) | 一种磷酸西格列汀片及其制备方法 | |
CN102988993B (zh) | 复方对乙酰氨基酚片主要辅料的筛选和组成及其制备方法 | |
CN105935358B (zh) | 一种沙库比曲缬沙坦缓释剂及其制备方法 | |
CN101843615A (zh) | 含有缬沙坦和苯磺酸氨氯地平的分散片及其制备方法 | |
CN102091069A (zh) | 缬沙坦和氨氯地平的复方制剂及其制备方法 | |
CN103142529B (zh) | 一种吲达帕胺缓释药物组合物及其制备方法 | |
CN113679684B (zh) | 磷酸西格列汀组合物、磷酸西格列汀片及其制备方法和用途 | |
CN103099873A (zh) | 绿咖啡豆提取物缓释片及制备方法 | |
CN103860511B (zh) | 一种含有厄贝沙坦和苯磺酸氨氯地平的药用组合物及其制备方法 | |
CN109010361A (zh) | 碳酸钙维生素d3制剂及其制备方法 | |
CN1269416C (zh) | 一种耐缺氧、抗疲劳的茶泡腾饮片及制备方法 | |
CN104069082B (zh) | 一种门冬氨酸钾片及其制备方法 | |
CN102836135B (zh) | 一种阿司匹林肠溶片及其制备工艺 | |
CN109125281A (zh) | 一种醋酸地塞米松口腔贴片及其制备方法 | |
CN104138363B (zh) | 一种硝苯地平缓释片及其制备方法 | |
CN102440969A (zh) | 一种灵芝酸单体t片剂及其制备方法 | |
CN103385862B (zh) | 一种酒石酸美托洛尔缓释片及其制备方法 | |
CN105012275B (zh) | 吲达帕胺缓释剂制备方法 | |
CN106943368A (zh) | 米氮平片剂及其制备方法 | |
CN106562937A (zh) | 一种辅酶q10软胶囊及其制备方法 | |
CN107252418B (zh) | 一种3d打印技术制备治疗低钾血症的口腔速崩片的方法 | |
CN105310992A (zh) | 苯磺酸左旋氨氯地平盐水合物的片剂组合物、由其制成的片剂及相关制备方法 | |
CN104434932B (zh) | 一种硫酸氢氯吡格雷阿司匹林片药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C53 | Correction of patent of invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Chen Yaqin Inventor after: Wang Hong Inventor after: Liu Qiang Inventor after: Shi Xiuqin Inventor after: Yan Yan Inventor after: Wang Huiying Inventor before: Chen Yaqin Inventor before: Wang Hong Inventor before: Liu Qiang Inventor before: Shi Xiuqin Inventor before: Yan Yan Inventor before: Wang Huiying |